Reinventing the fight against bacteria, one phage at a time.

Conceptual Mechanistic Framework for Induced Native Phage Therapy (INPT) in Multidrug-Resistant Infections and Tumor-Associated Microbiomes Induced Native Phage Therapy (INPT) and related Inducen® formulations are intended to function as an important key component of a broader, integrative, non-cytotoxic therapeutic strategy. They are not proposed as standalone cancer treatment, but as adjunctive interventions designed to address contributory microbial drivers of oncogenesis while preserving commensal microbiome integrity. List of 10 Bacterial Infections That Can Instigate Cancer Below is a reproduced and updated list of various bacterial infections known or suspected to instigate cancer, based on our previous discussions and peer-reviewed research from the web search results. The list focuses on key bacteria, the associated cancer types, and the mechanisms by which they initiate or promote carcinogenesis. These mechanisms often involve chronic inflammation, DNA damage, immune...

Stability of bacteriophages in spray-dried polymeric formulations: Effect of excipient polyvinylpyrrolidone glass transition temperature and molecular weight (A summary) Abstract: The development of stable dry-state bacteriophage formulations is essential for expanding the therapeutic applicability of phage therapy and reducing cold-chain dependency. This study evaluates the long-term stability of spray-dried PEV1 bacteriophage formulated with polyvinylpyrrolidone (PVP) polymers of varying molecular weights (K15, K25, K40, K100). Formulations were stored for 180 days under controlled temperature (4, 22, and 40 °C) and relative humidity (15–53% RH) conditions. Differential scanning calorimetry demonstrated that glass transition temperature (Tg) increased with polymer molecular weight but decreased significantly with increasing humidity, consistent with water-induced plasticization. At low humidity (15% RH), all formulations maintained high stability (≤1 log10 titre loss) at 4 and 22 °C....

J AFRAL Phage Summit 2026 19–21 May 2026 | Ljubljana, Slovenia As antimicrobial resistance (AMR) accelerates and antibiotics lose ground, the world urgently needs new therapeutic solutions that are both effective and patient‑centred. Bacteriophages are emerging as one of the most promising tools we have. What the phage field needs most today is deeper global connection, stronger collaboration, and a shared roadmap for turning scientific progress into real‑world therapies. And that is exactly what the JAFRAL Phage Summit 2026 will deliver. A Global Meeting Shaping the Future of Phage Therapy From clinicians, pharmacists and infectious disease specialists to biotech innovators, regulatory authorities, researchers and industry leaders, this summit brings together every key stakeholder driving the next era of phage therapy. Over three intensive days, participants will explore new developments, share clinical experiences, and accelerate the translation of phage science into safe...